GOOD DIVIDEND
PHARMA 7081 Share Price
RM3.39
52 Weeks Range : 1.48 - 6.69
3.8/10
(Expert Score)
Product is rated as #14 in category BM Health Care
PROS:
- Profitable business
- Small Dividend Payout
- Very High Trading Value
CONS:
- Very Low Price-to-Tangible
- Company in Debt
- Very High Gearing
klse: Pharmaniaga Bhd
Corporate Information
Board : Main
Shariah : Shariah Compliant
Sector : Ringgit Consumer Healthcare
Address: No. 7, Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja Selatan, Seksyen 7, Shah Alam, 40000, Selangor
Contact: +603-33429999
Website: https://www.pharmaniaga.com/
Corporate Background
Pharmaniaga Berhad is an investment holding company. The Company, through its subsidiaries, manufactures, markets, and distributes pharmaceutical and medical products to government hospitals and private institutions. Pharmaniaga also provides web portal services for online trading of health care products.
Genaral Info: PHARMA 7081
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 17/03/21 | 634,583 | -13,506 | -6,331 |
| 19/11/20 | 624,804 | 4,093 | 1,442 |
| 19/08/20 | 645,763 | 14,326 | 9,979 |
| 19/05/20 | 819,921 | 30,880 | 22,399 |
| 20/02/20 | 715,683 | -238,474 | -178,598 |
| 20/11/19 | 716,849 | 3,885 | 481 |
| 23/08/19 | 601,890 | 12,481 | 9,281 |
| 16/05/19 | 786,108 | 30,243 | 19,617 |
| 21/02/19 | 596,644 | 11,940 | 4,437 |
| 19/11/18 | 587,660 | 17,603 | 15,051 |
| 17/08/18 | 582,729 | 11,970 | 5,394 |
| 16/05/18 | 617,923 | 28,707 | 17,586 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 2,725,071 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | 26,269 |
| Last 4 Quarter EPS (sen) | 10.51 |
| Last 4 Quarter PER | 33.77 |
| Last 4 Quarter Dividend (sen) | 11.00 |
| Last 4 Quarter Dividend Yield (%) | 3.24 |
| Net Tangible Assets (RM) | 1.29 |
| Goodwill (RM) | 193,810 |
| Cash (RM’000) | 36,540 |
| Debt (RM’000) | 733,290 |
| Total Debt (RM’000) | 1,400,000 |
| Net Assets (RM’000) | 345,560 |
| Current Ratio | 0.79 |
| Quick Ratio | 0.27 |
| Cash Ratio | 0.02 |
Technical
Technical Analysis
| MACD (26 vs 12) | -0.216 |
|---|---|
| Exponential Moving Average 5 | 3.249 |
| Exponential Moving Average 20 | 3.422 |
| Exponential Moving Average 90 | 4.205 |
| Relative Strength Index 14 | 0.30 |
| Stochastic %D 3 | 0.24 |
| Stochastic %K 14 | 0.23 |
10 reviews for PHARMA 7081
Show all
Most Helpful
Highest Rating
Lowest Rating
The Star –
Shares of Pharmaniga Bhd and Duopharma Biotech Bhd climbed in active trade on Wednesday as the companies sign agreement with the Government to supply Covid-19 vaccine. Pharmaniaga, one of the top gainers on Bursa Malaysia this morning, rose 3.01%, or 15 sen to RM5.13. Pharmaniaga said it would be supplying 12 million doses of Covid-19 vaccines developed by China’s Sinovac Life Sciences Co Ltd
The Star –
Shares in Pharmaniaga Bhd rose over 5% in early trade Thursday following its partnership with China’s Sinovac Life Sciences Co Ltd. The pharmaceutical company added 5.62%, or 29 sen to RM5.45. In the past one year, the counter has risen some 156%. Pharmaniaga has signed an agreement with China’s Sinovac to purchase 14 million doses of ready-to-fill COVID-19 vaccines and later to manufacture the vaccine domestically. The group expects the vaccine to be distributed to the public by the end of March this year. This will cover 22% of the country’s total population.
The Edge –
AmInvestment Bank Bhd (AmInvest) believes that Pharmaniaga Bhd would be the main distributor of the Covid-19 vaccine to local hospitals, and may appoint other companies to help distribute the vaccine nationwide. In terms of fill-finish companies, AmInvest said while a deal concerning Covid-19 vaccine’s fill-finish process has yet to materialise, the government seems to favour Duopharma Biotech Bhd and Pharmaniaga to undertake these processes.
BURSA MALAYSIA –
In comparison with the immediate preceding quarter, the Group recorded a lower revenue of RM625 million for the current quarter. This was mainly due to reduced demand from both the concession business and the Indonesia business as a result of the Covid-19 pandemic, which saw limited access to doctors, clinics, pharmacies and hospitals. The Group recorded a PBT of RM4 million, compared with RM14 million in the immediate preceding quarter
The Edge –
Shares in Pharmaniaga Bhd rose as much as 4.06% this morning after the pharmaceutical company marked its first task in the fill-and-finish vaccine process when it signed an agreement with Serum Institute of India Pvt Ltd, the world’s largest vaccine manufacturer by the number of doses produced. The two companies signed a memorandum of agreement, which will enable Pharmaniaga to purchase pneumococcal vaccines from Serum and subsequently use the technology and know-how licensed by them for the filling and finishing process. The fill-and-finish product will be marketed, distributed and sold exclusively in Malaysia by Pharmaniaga.
BURSA MALAYSIA –
In comparison with the immediate preceding quarter, the Group recorded a lower revenue of RM646 million for the current quarter. This was mainly due to reduced demand from both the concession business and the Indonesia business as a result of the Covid-19 pandemic, which saw limited access to doctors, clinics, pharmacies and hospitals. The Group recorded a PBT of RM14 million, compared with RM31 million in the immediate preceding quarter.
REMUNERATION STUDY –
In Financial Year End 2019, the directors’ remuneration was 1.93 million. It was low compared to average in listed companies, considering the employees’ remuneration of 195.9 million and auditor’s remuneration of 570 thousands
BURSA MALAYSIA –
In comparison with preceding quarter, the Group’s revenue increased to RM820 million for the 1Q2020. This was primarily due to stronger demand from Government and private hospitals in Malaysia and Indonesia. The Group post a PBT of RM31 million compared with a deficit of RM238 million in preceding quarter. The loss was due to the revision in useful life of the rights to supply and provision of stock write-off as a result of the voluntary Ranitidine product recall.
BURSA MALAYSIA –
The Group recorded a revenue of RM716 million for the current quarter as compared to RM717 million in preceding quarter. However, the Group recorded a LBT of RM238 million for the current quarter as compared to PBT of RM15 million in preceding quarter due to the revision in useful life of the rights to supply and provision of stock write off as a result of the voluntary Ranitidine product recall.
INVESTING MALAYSIA –
PHARMA 21 JAN 20 – Pharmaniaga Bhd says its managing director (MD) Datuk Farshila Emran will leave the company when her contract expires at the end of March this year, confirming a report by theedgemarkets.com earlier today.
Investing Malaysia –
Average investing volume for Pharmaniaga Bhd in the past three months in stock market was 296.7k lots
Investing Malaysia –
PHARMA gets a score of 10.92 in our equity and assets quality test based on current share price of RM1.9
Investing Malaysia –
Pharmaniaga Bhd gets a score of 10.15 in our stability test after the balance sheet, money statement study
Investing Malaysia –
Stock code of 7081 in Bursa Malaysia declared adjusted 6.42% dividend yield in past few years
Investing Malaysia –
PHARMA is estimated to have a profit consensus of 44.98 millions, with an adjusted market capitalization of 478.05 millions
REMUNERATION STUDY –
In Financial Year End 2018, the directors’ remuneration was 2.32 million. It was low compared to average in listed companies, considering the employees’ remuneration of 164.6 million and auditor’s remuneration of 620 thousands